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ABSTRACT 
Analytical interest of oleanolic acid determination in human serum has increased owing to 
the increasing interest in pharmaceutical research by pharmaceutical properties. A simple, 
specific, precise and accurate GC method with flame ionization detection is developed and 
validated for the determination of oleanolic acid (OA) in human serum (HS). To an aliquot of 
HS, internal standard was added and a combination of liquid/liquid extraction with a mixture 
of diethyl ether-isopropyl alcohol, filtration, and consecutive GC resulted in separation and 
quantification of OA. The organic phase was analyzed by a GC system equipped with a 30 x 
0.25 mm i.d. Rtx-65TG capillary column and FID detection. Total chromatographic time was 
ten minutes and no interfering peaks from endogenous components in blank serum were 
observed. The OA/internal standard peak area ratio was linearly fitted to the OA 
concentration (r = 0.992) over the range 10-1500 ng/mL. The mean serum extraction 
recovery of OA was 96.7±1.0% and lower limit of quantification based on 5mL of serum was 
10.7 ng/mL. The intraday coefficient of variation ranged from 1.3 to 3.6% and interday 
varied from 1.4 to 4.5%. The developed method was used to study the pharmacokinetics of 
OA after oral administration in humans. The assay was simple, sensitive, precise and accurate 
for the use in the study of the mechanisms of absorption and distribution of OA in humans.  
 
 
Keywords: betulinic acid; GC-FID determination; human serum; oleanolic acid; 
pharmacokinetics. 
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1. Introduction 
Oleanolic acid (3β-hydroxy-olean-12-en-28-oic acid), a secondary metabolite ubiquitously 
distributed throughout the plant kingdom, as free acid or forming part of triterpenoid saponins 
is isolated from more than 120 plant species. In particular, there are 146 families, 698 genus 
and 1620 species of plants containing OA (Fai et al., 2009). It is noteworthy that OA is the 
major triterpenic component and appears in very important quantities as free acid in olive leaf 
(ca. 3 % dry matter) (Guinda et al., 2010). This triterpene displays various pharmacological 
effects (Dzubak et al., 2006; Pollier et al., 2012) being this way, a leading compound for the 
development of new multi-targeting bioactive agents. The pharmacological relevance of OA 
has increased during the last two decades. Recently, triterpenes supplements, including OA, 
are reported to have antineoplasic effects and to reinforce the activity of anticancer drugs 
against several tumor cell lines (Yamai, et al., 2009; Ma et al., 2014). In addition, OA exerts 
beneficial effects against diabetes and metabolic syndrome through complex and 
multifactorial mechanisms according to Castellano et al. (2013). Triterpene treatment 
possesses therapeutic effects on diet-induced hyperlipidemia by inhibiting the intestinal 
absorption and storage of cholesterol. Recently, Wang et al., (2013) reported that OA 
improves hepatic insulin resistance via antioxidant, hypolipidemic and anti-inflammatory 
effects. Furthermore, OA has been successfully used as an orally administrated drug to treat 
human liver diseases in China (Liu et al., 2005). The administration of the natural 
triterpenoid OA reduces and limits the severity and development of experimental 
autoimmune encephalomyelitis. Therefore, OA therapy might be of clinical interest for 
human multiple sclerosis and other Th1 cell mediated inflammatory diseases (Martin et al., 
2010). Consequently, OA is of increasing interest in pharmaceutical research circles because 
it may have distinct pharmaceutical properties of its own or provide a basis for the 
development of new pharmaceutical drugs by partial structure variation. Until now, limited 
researches of OA determination in HS (Song et al., 2006; Chen et al., 2010; Rada et al., 
2011) and in experimental animal serum (Jeong et al., 2007; Ji et al., 2009) are reported. The 
technique employed by these authors to determinate OA in serum is mainly HPLC-MS. 
However, to our knowledge, there is still no report on the determination of OA on HS 
samples by GC-FID. 
At the view of these precedents, this study had two objectives: to develop and validate a 
rapid, sensitive and accurate method for the GC-FID determination of OA in HS and to apply 
this method to a pharmacokinetic study of OA after oral administration. Furthermore, in the 
present study the binding percentage with human serum proteins (HSP) was also investigated. 
 
2. Experimental 
2.1.  Materials and Reagents 
Oleanolic acid (98% pure, Fig. 1b) was obtained in our lab (Guinda et al., 2001). Betulinic 
acid (97% pure, Fig. 1a) used as internal standard (IS) was purchased from Sigma Chemical 
Co. (St. Louis, MO, USA). Methanol was of chromatographic grade. All the other reagents 
were of analytical grade. Distilled water, prepared from demineralised water, was used 
throughout the study. 
2.2. Sample preparation 
To 5 mL of serum sample, 12.5µL methanolic solution of betulinic acid (0.5 mg/mL, IS) was 
added. The solution was mixed for 30 seconds and dry nitrogen was used to eliminate 
methanol traces. The mixture was filtered in a cellulose acetate membrane filter with a pore 
size 0.20 μm (AC02047BL). After the filtration was completed the sample was extracted with 
5.0 mL of 5% isopropyl alcohol in diethyl ether through vigorous vortex mixing for 3 min, 
followed by centrifugation at 3000 rpm for 10 min.  This extraction procedure was repeated 
three times. Supernatants were accurately combined and concentrated to dryness by 
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evaporation (Büchi Rotavapor R-205, Switzerland). The residue was derivatized by adding 
75 µl BSTFA [N, O-bis-(trimethylsilyl) trifluoroacetamide] +1 % TMCS 
(trimethylchlorosilane), 25 μL of pyridine and by sonication at 40 ºC for 10 min (ultrasonic 
bath ULTRASONS H-D, Pselecta, Spain). A 1 μL aliquot of the derivatized sample was 
injected into the GC. 
2.3.  GC/FID Analysis 
2.3.1. GC-MS identification of oleanolic acid. The analysis of silylated OA was performed 
using a coupled gas chromatography-mass spectrometry detector (GC-MS) QP2010 Ultra 
(Shimadzu Europa GmbH) fitted with an AOC-20i autosampler, an ion source of electron 
impact and a quadrupole detector. The splitless mode was used and the injector temperature 
was set at 290 °C. Helium as a carrier gas at a pressure of 53.1 kPa and a flow of 1 mL/min 
was used. The oven temperature program was as follow: initial temperature 50 °C for 1 min, 
50-200 °C at 40 °C/min , 200-280 °C at 10 °C/min and finally  held for 2 min. Total run time: 
14,75 min. The MS conditions were: interface temperature: 280 °C; ion source temperature: 
220 °C; electron impact: 70 eV; acquisition mode: scan (m/z 50-600). The identification of 
OA were accomplished by comparing the retention times and abundance ratios of two 
fragments ions (203 and 189 m/z). 
2.3.2. Determination of oleanolic acid.   The quantification was carried out by a 
modification of the method previously established in our lab (Rada et al., 2011).  One 
microliter of the silylated sample was injected in an Agilent 6890N GC (Agilent 
Technologies, Santa Clara, CA), equipped with a Rtx-65TG Crossbond capillary column (30 
m x 0.25 mm I.D.; 0.1 mm film thickness;) coated with 35 % dimethyl and 65 % diphenyl 
polysiloxane as stationary phase (Restek, Co.; Bellefonte, PA) and a FID detector. The 
injection was realized in split mode and hydrogen was used as carrier gas (pressure at column 
head 140 kPa). The oven temperature was isothermally established at 260 ºC for 10 min. The 
injector and detector temperatures were established at 300 ºC. These triterpenic compounds 
were previously identified in our laboratory by means of GC-MS using the same Rtx-65TG 
Crossbond capillary column and a Finnigan MAT95’s (Finnigan, Bremen, Germany) high 
resolution mass spectrometer interfaced with a HP 5890 Series II GC (Guinda et al., 2004). 
2.4. Assay validation 
2.4.1. Limits of Detection (LOD) and Quantification (LOQ). Detection and quantitation 
limits were calculated by measuring the analytical background response, running six blank 
serum samples using maximum sensitivity allowed by the system. The signal-to-noise ratio 
was used to determine the LOD, and it was estimated as the concentration of oleanolic acid in 
serum samples that generated a peak with an area at least 3 times higher than the baseline 
noise. The LOQ was afterward validated by the analysis of six serum samples known to be 
near the LOQ. 
2.4.2.  Stability. Drug free serum was spiked with known amount of the drug to achieve the 
concentration of 10, 100, 200, 300, 500, 1000, 1500 ng/mL (n=4) and stored at 4ºC. Those 
samples were used to investigate the stability of OA over a period of two months. No internal 
standard was added prior to the analysis. 
2.4.3.  Specificity. The specificity of the method was determined by comparing the 
chromatograms obtained from the samples containing OA and internal standard with those 
obtained from blank HS. Four samples from five lots of blank HS were processed with and 
without the OA and IS to evaluate presence of interfering peaks. 
2.4.4.  Linearity and range. The linear detector response for the assay was tested. The 
determination (n = 4) from seven concentration levels (10, 100, 200, 300, 500, 1000, 1500 
ng/mL) of the analyte were made. Detector response was correlated against analyte 
concentration by least squares regression. A weight of 1/y was used to determine slopes, 
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intercept and correlation coefficients. The minimum acceptable coefficient to establish 
linearity was set at 0.95 a priori. 
2.4.5.  Precision and accuracy. The precision of the assay was determined at low, medium 
and high concentrations of OA by replicate analyses of the quality control (QC) samples. 
Intra-day precision was determined by replicated analysis of each QC sample on 1 day (n = 
5). Inter-day precision was determined by replicated analysis on five consecutive days (n = 1 
series per day). Accuracy is defined as the relative deviation in the calculated value of a 
standard from that of its true value expressed as a percentage (RE %). Precision was 
calculated as inter and intra-day coefficient of variation [% CV = (SD/mean) x100]. 
2.4.6.  Recovery. The extraction recovery of oleanolic acid was determined at low, medium 
and high concentrations, respectively. Recovery was calculated by comparison of the peak 
areas of oleanolic acid extracted from serum samples with those of injected standards.  
2.5.  System suitability test  
Prior to running each batch of clinical serum samples, the instrument performance (e.g. 
sensitivity, reproducibility of chromatographic retention and separation, plate number and 
tailing factor) was determined by analysis of the reference standard of OA, IS, blank serum 
and serum spiked with OA and IS (US Department of Health and Human Services et al., 
2001). 
2.6. Application of the GC Method and Pharmacokinetic Study 
2.6.1.  Clinical study design and pharmacokinetic analysis. To study the pharmacokinetic 
profile of OA, aliquots (5mL) of HS samples provided by Dr. Ruiz-Gutierrez (Instituto de la 
Grasa-CSIC) was analyzed. Nine healthy men aged 26.2 ± 4.3 with body mass index 23.7 ± 
2.0 kg/m2 participated in the study. The subjects were recruited after screening for fasting 
plasma triglycerides, cholesterol, and glucose concentration, all of which were within the 
normal limits proposed by the Atherosclerosis, Hypertension, and Obesity in Youths 
Committee (Pearson et al. 2002). Medical history verified that volunteers did not suffer from 
any digestive or metabolic disorder. The participants gave written informed consent to a 
protocol approved by the Institutional Committee on Human Research of the Virgen del 
Rocío University Hospital, Sevilla-Spain. The samples were obtained as described by 
Cabello-Moruno et al. (2007). Each one of healthy volunteers received a test meal including 
70 g of pomace olive oil containing 30 mg of dissolved OA, after overnight fasting. Blood 
was sampled pre-dose and at 1.0, 2.0, 3.0, 4.0, 5.0, 6.0 and 7.0 hour post-dose for 
determination of serum concentration of OA and pharmacokinetic parameters were 
calculated. The serum concentrations of OA at different time points were expressed as mean 
± SD (n = 9), and the mean concentration-time curve was plotted. One-compartment 
pharmacokinetic parameters were calculated for OA. The maximum serum concentration 
(Cmax) and the time to reach the peak concentration (tmax) were obtained directly from the 
observed values. The apparent elimination rate constant (Ke) was calculated using fitting 
mean data at four terminal points of the serum concentration profile with a log-linear 
regression equation using the least-squares method. The t1/2 was calculated as 0.693/Ke. The 
area under the serum concentration-time curve from zero to the time of the final measurable 
sample (AUC0 - t) was calculated using the linear-trapezoidal rule up to the last sampling point 
with detectable levels (C). The area under the serum concentration-time curve from zero to 
infinity (AUC0 - ∞) was calculated using the trapezoidal rule with extrapolation to infinity with 
Ke. The mean residence time (MRT) was calculated as the ratio of the area under the first 
moment curve (AUMC0 - t) to AUC0 - t. The apparent total body clearance (CL) after oral 
administration was calculated using the equation CL = Dose/ AUC0 - t. The volume of 
distribution (Vd) after oral administration of OA was calculated using the equation Vd  = 
Dose/C0. 
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2.6.2. Oleanolic acid binding study. The extent of binding of OA to serum proteins was 
investigated by spiking blank HS with OA at 1, 5 and 20 μg/mL (each level in triplicate) and 
then allowing equilibration to take place for 15 min at 37 ºC prior to ultrafiltration. An 
Amicon (Millipore, Bedford, MA, USA) YM-30 ultrafiltration centrifuge filter with a 
molecular cut-off of 30 000 was used to separate the protein-bound from the free OA. A 2 
mL aliquot of each equilibrated serum solution was placed in a filter unit and was centrifuged 
at 3000 g (37ºC) for 30 min. Next, a 500 μL aliquot of each ultrafiltrate was subjected to the 
protocol described in the section 2.5 for the determination of the concentration of free OA. 
 
3. Results and discussion 
The present study covers OA determination in biological samples, binding percentage and 
pharmacokinetics studies.  
3.1. Method development  
Liquid-liquid extraction was used for the sample preparation in this method to avoid matrix 
interferences. Various organic solvents, such as ethyl ether, ethyl acetate, dichloromethane, 
and their mixtures in different combinations and ratios were evaluated. Finally, a mixture of 
ethyl ether–2-propanol (95:5, v/v) was found to be optimal for producing a clean blank serum 
chromatogram and yielding the highest recovery for OA and the betulinic acid (IS).  The 
extraction procedure was repeated three times and a fourth extraction was carried out to 
confirm the extraction completeness. No OA was detected in the fourth extraction. To 
improve the recovery of OA, the serum sample was micro-membrane filtered before the 
extraction procedure. The filtration by 0.20 μm cellulose acetate membrane of HS retained 
proteins, which helped to release into the extracting solvent the bound organic components 
with Van der Waals interaction (Peng et al., 2014), including OA. The addition of this 
previous step in the method, also avoided the possible matrix interferences especially in the 
identification by GC-MS. Matrix effects were evaluated by comparing the peak areas of 
analyte in extracted samples of blank serum spiked after extraction with the corresponding 
areas obtained by direct injection of standard solutions. No endogenous species interfered 
with the analyte and IS. 
For the gas chromatographic analysis of OA, a preliminary derivatization process is 
necessary due to its low volatility and high molecular weight. Derivatization of the terpene 
was time-reduced at only 10 min by involving sonication of the sample at 40 ºC. The 
experimental chromatographic variables were optimized. The operating conditions are 
described in Section 2.3. Splitless and split injections were tested to check the influence of 
the split ratio on the GC–FID analysis. The sensitivity depends on the volume injected and on 
the split ratio. In this work, to prolong the shelf-life of the chromatographic column, the 
volume injected was 1 μL and the split ratio was 1:25.  For more sensitive determinations, 2 
μL or even larger volumes can be injected and the split ratio can also be decreased. Betulinic 
acid, a pentacyclic triterpene as well as OA, was used as internal standard due to its chemical 
behaviour similar to that of the target analyte (relative response factor (RRF) = 1). 
Identification of the chromatographic peaks was made by comparison of mass spectra with 
those provided by standard solutions and also by GC retention times. The GC-MS 
identification of OA trimethylsilyl derivative were accomplished by comparing the retention 
times and abundance ratios of two fragments ions (203 and 189 m/z). 
Representative GC chromatograms of blank serum and serum spiked with the terpenic acids 
(oleanolic and IS) are shown in Fig. 2a and 2b, respectively. The retention times of OA and 
the IS were 7.0 and 7.5 min, respectively. It can be observed that blank serum chromatogram 
shows no peak at these retention times, being this way the assay free of interference from 
compounds in the biological matrix. A GC chromatogram of HS sample after OA oral 
administration is presented in Fig. 2c. This sample has been collected in the pharmacokinetic 
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study, 2 hours after administration of 30 mg of OA in 70 g of pomace olive oil, as described 
in section 2.6. As shown in Figure 2, the selected chromatographic conditions resulted in a 
good chromatographic resolution, with good peak separation. In addition, the good 
chromatographic separation between the studied compounds (OA and BA) and other 
important HS compounds such as cholesterol derivatives evidence the interest of this method. 
However, to our knowledge, there is still no report on the gas chromatography determination 
of OA in serum samples. The developed and validated GC method resulted rapid, sensitive, 
and accurate for the determination of OA in HS.  This method is very interesting for future 
clinical studies and research using common techniques; furthermore it could be applied to 
several aqueous matrices. 
There are a limited number of reports on the analysis of OA in human samples (Song et al., 
2006; Rada et al., 2011) and only a few reports in animal serum (Jeong et al., 2007; Ji et al., 
2009) the reported articles were based mainly on HPLC-MS determination. Jeong et al., 
(2007) evaluated the pharmacokinetics of OA after intravenous and oral administration in rats 
using the HPLC-MS method reported by Song et al., (2006). As well, the same method was 
used by Ji et al., (2009) to study OA pharmacokinetics in experimental animals (mice, rats, 
rabbits and dogs) and prediction of human pharmacokinetics. In addition, Chen et al., (2010) 
reported pharmacokinetic profiles of OA formulations in healthy Chinese male volunteers 
using the Song´s method. 
In our previous work (Rada et al., 2011) a method for separation, identification and 
quantification of pentacyclic triterpenoids in HS employing HPLC technique was reported. 
The quantification limits were in the same range as the ones obtained in the present study, 
10.7-14.3 ng/mL, and the linearity values ranged up to 1 µg/mL.  
Knowing that the chromatographic determination of OA by HPLC using UV or fluorescence 
detection is limited since this pentacyclic triterpene lacks UV-absorbing chromophores; 
application of GC-FID resulted appropriate because it does not depend on the presence of a 
particular chromophore in the molecule. It is worth noting that the recovery of OA by GC-
FID method described is higher than that obtained by Rada et al., (2011). 
Song et al. (2006) reported a method for the analysis of OA in human plasma by HPLC-MS. 
The assay was validated in the concentration range of 0.02–30.0 ng/mL for OA when 0.5 mL 
of plasma was determined. The validation of method described in this study was stablished in 
the range of 10-1500 ng/mL when 5 mL of HS was analysed by GC-FID. The relative 
standard deviation was less than 5 % and the limit of quantification (LOQ) was 10.7 ng/ml, 
whereas the relative standard deviation by HPLC-MS was less than 15 % and the limit of 
quantification was 0.02 ng/mL. Furthermore, the recovery results of the samples analysed by 
the method described hereby is higher than the results obtained by HPLC-MS.  In consonance 
with these previous methods, the technique described in the present study enables the GC–
FID analysis of OA in HS with good precision and accuracy. On the other hand, taking into 
consideration that GC is a technique widely established in laboratories for numerous 
applications, easy handling and of low cost, which also avoids the use of solvents resulted 
another possible choice for our purpose. In addition, GC presents high resolution power (N ~ 
1.3 x 106) and high linear range (FID) and the retention index standards can be applicated, 
which is standardized using Kovats index, LC is still lacking. 
3.2.  Calibration and validation  
The intra- and interday precision and accuracy results are shown in Table 1. The intra- and 
interday precision was less than 3.3 and 4.5 %, respectively, and the accuracy was within 3.6 
% for the QC samples. The values obtained were lower than the limits required for biological 
sample analysis. The results indicated that the LOQ of 10.7 ng/mL was achieved. The results 
showed that the extraction recoveries of OA from HS were from 95.7 to 98.4 at 
concentrations of 20 and 1000 ng/mL, respectively. The mean recovery was 96.7±1.0 %. 
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Results of the stability experiments indicated that OA storage at – 20 ºC was stable at least 
four weeks in HS. This storage period and conditions should be adequate for most in vivo 
studies of OA. In addition, the corresponding relative errors from the same three 
concentrations indicated that OA was stable in HS after three freeze-thaw cycles.  
3.3.  Application of the method in pharmacokinetic studies 
The developed and validated GC-FID method was used to determine OA in HS after oral 
administration of pomace olive oil at a dose containing OA 30 mg. Using the established GC 
method with the degree of sensitivity (LOQ of OA, 10.7 ng/mL) a pharmacokinetic study of 
OA in humans was successfully performed. The OA concentration analysed resulted above 
the LOQ during 7 h post-dose. The mean serum concentration-time curve profile is shown in 
Figure 3 and its pharmacokinetic parameters are listed in Table 2. The pharmacokinetic 
results show that the absorption of OA presents the peak concentration at 3.0 h (tmax) after 
oral administration of prepared meal. These data are in accordance to Chen et al., (2010), in a 
randomized, crossover and self-control study, where 18 male volunteers received orally 20 
mg of OA.  Likewise, the mean residence time (MRT) reported by this author is very similar 
(13.6 ± 8.6 and 18.3 ± 11.8 h for the OA normal tablets and dispersible tablets, respectively). 
However, the results obtained in our study for the AUC and the Cmax are higher. These results 
could be due to the higher dose (50 %) administered to volunteers in our assay. It is 
noteworthy, that the curves of OA concentration versus time, in both trials have the same 
profile. The pharmacokinetic parameters for the administered OA dose revealed distribution 
volumes (Vd) of 81.4 ± 9.7 L, and lengthy elimination half-lives of 4.6±1.1 h. The 30 mg OA 
oral dose yielded total clearance of 35.1 ± 4.2 L/h. The different oral administration of OA 
single dose studied by Song et al. (2006) and Chen et al., (2010), were 40 mg-capsules and 
20 mg normal/ dispersible tablets, respectively and the OA concentrations determined in 
serum volunteers ranged between 12.1 ± 6.8 and 18.9 ± 8.0 ng/mL. In our pharmacokinetic 
study was tested a single dose of OA within the above-mentioned range (30 mg-oil solution) 
and the concentrations of OA determined in HS volunteers were higher (598. 2 ± 176.7 
ng/mL). In this experience, the higher values obtained could be due to the way that the 
triterpenic acid is supplied, OA was provided in solution in an edible vegetable oil. When 
supplied as a capsule or tablet, particle size of OA is higher than the molecular size present in 
the oil and presents different bioavailability. We assume that the smaller size of the OA 
facilitates the absorption of the terpene. Obviously, alternative formulations are possible and 
it will be of interest to examine the pharmacokinetics of OA in other formulations. This is the 
first report of OA determination in HS by GC-FID and the utility of this method for the 
quantitative analysis of OA in HS in support of in vivo studies was demonstrated. 
3.4. Oleanolic acid binding study 
HS albumin is an important plasma protein responsible for the binding and transport of many 
endogenous and exogenous substances such as hormones and fatty acids, as well as foreign 
molecules such as drugs. It is known that the distribution, free concentration and the 
metabolism of various drugs are strongly affected by drug–protein interactions in the blood 
stream. Many drugs and other bioactive small molecules bind reversibly to albumin and other 
serum components, which then function as carriers. In addition, thermodynamic analyses 
show that the basic forces acting between bovine serum albumin and triterpenoids are 
hydrogen bonds, van der Waals forces, and hydrophobic interactions (Peng et al., 2014; 
Bhattacharya et al., 2000; Subramanyam et al., 2009) anticipated that the complexation of 
plant triterpenoids with protein may be exploited as a biologically relevant model for 
evaluating the physiologically applicable no-covalent complexes in vivo examination of 
triterpenoid properties such as accumulation, bioavailability, and distribution.  In a first step 
to learn more about the way of interaction of OA and the HSP we studied the absorbance 
spectrum of the system OA-HSP (Rada et al., 2011). Furthermore, an additional study was 
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made to investigate the extent of protein binding of OA in HS was using the ultrafiltration 
method. In accordance to Peng et al., (2014), our results showed that OA was highly protein-
bound in HS. The bound fraction was 98.8 ± 3.2, 98.9 ± 2.5 and 98.9 ± 0.3 % at 1, 5 and 20 
µg/mL concentrations. 
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Legends 
 
Figure 1. Chemical structures of triterpenic compounds determined in HS: (a) betulinic acid 
(b) oleanolic acid.  
Figure 2. GC Chromatograms for the determination of OA in HS. (a) Blank HS sample; (b) 
blank HS sample spiked with OA at 1µg/mL and internal standard; (c) HS sample after oral 
administration of OA (30mg). (1) Cholesterol; (2) OA; (3) IS. 
Figure 3. Concentration-time curve of OA in HS after oral administration of 30mg. Each 
point and bar represent mean±SD (n=9). 
12 
 
 
Table 1. , Intra-day and inter-day accuracy, precision and recovery of oleanolic acid (OA) from human serum (HS) (n=5) 
Added to serum  Absolute recovery  Intra-daya  Inter-dayb 
(ng/mL)  Mean (%) (R.S.D.%)  RE% Precision (R.S.D.%)  RE% Precision (R.S.D.%) 
20.0  95.5 3.7  -3.6 3.3  3.2 4.5 
100.0  96.0 2.2  2.8 2.2  -1.3 2.6 
500.0  96.8 2.1  2.3 1.9  3.4 1.9 
1000.0  98.6 1.5  1.9 1.3  0.3 1.4 
a The sample was analyzed five times within one day. 
b The sample was analyzed over five consecutive days.
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Table 2.  Pharmacokinetic parameters (mean ± SD) of OA in HS after oral administration at a dose of 30 mg (n = 9) 
parameters Cmax 
(ng/mL) 
tmax 
(h) 
Ke 
(1/h) 
t1/2 
(h) 
AUC0-t 
(ngh/mL) 
AUC0-∞ 
(ngh/mL) 
MRT 
(h) 
CL 
(L/h) 
Vd 
(L) 
mean ± SD 598.2±176.7 3.0±0.8 0.43±0.04 4.61±1.1 3025.2±847.1 3181.9±894.3 8.89±2.67 35.1±4.2 81.4±9.7 
Cmax, maximum serum concentration; tmax, peak concentration time; Ke, elimination rate constant; MRT, mean residence time; AUC, area under the curve; t1/2, elimination 
half-lives; CL, clearance; Vd, volume of distribution. 
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